Phase 3 trial results bring hope for patients with IgA nephropathy

IgA nephropathy is the most common inflammatory kidney disease among the glomerulonephritides. Berger and Hinglais described the disease in 1968.1 IgA nephropathy is generally considered a benign kidney disease, which is true if compared to many vasculitides, but false in view of a recent analysis of real-world data from the UK National Registry of Rare Kidney Diseases (RaDaR),2 which found that patients with IgA nephropathy had a median kidney survival time (until kidney failure, all-cause death, or end of follow-up) of only 11·4 years (95% CI 10·5–12·5).